Research
Hormonal
Congenital leptin deficiency causes severe early-onset obesity driven by hyperphagia and impaired satiety, which is reversible with daily recombinant human leptin injections.
If you have a confirmed genetic diagnosis of leptin deficiency, daily leptin injections can normalize your metabolism and stop the intense drive to eat. This is a targeted medical treatment, not a general weight loss strategy.
StrongSupportsVERY_HIGH confidence
Congenital leptin deficiency can be successfully treated with daily injections of recombinant human leptin, correcting all the metabolic abnormalities seen in these patients... The major effect of leptin administration is on food intake, with normalization of hyperphagia and enhanced satiety.
Why this rating
Based on clinical trials in patients with confirmed genetic mutations showing complete metabolic correction.
Source
Genetic approaches to understanding human obesity
Shwetha Ramachandrappa et al. · Journal of Clinical Investigation · 2011
DOI 10.1172/jci46044
narrative_reviewCited 193×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- MC4R mutations are the most common cause of monogenic obesity, found in 5-6% of severe early-onset obesity cases, and lead to hyperphagia, increased lean mass, and accelerated linear growth.Strong
- FTO gene variants are associated with increased energy intake rather than energy expenditure, leading to a 3-4 kg higher body weight and 1.67-fold increased obesity risk in homozygotes.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →